ADC Development Services Targeting CD56

CD56 has emerged as an attractive molecular candidate for the design of novel, targeted therapeutic strategies for improving patient outcomes in various hematological malignancies as well as solid tumors. It is reported that ADCs targeting CD56 have been successfully developed and applied clinically with promising results. With integrated antibody development and engineering technology, abundant linker-payload resources and advanced bio-conjugation strategies, Creative Biolabs offers a comprehensive set of customized anti-CD56 ADC development services from ADC preparation to further analysis and characterization services. In addition, the catalog Anti-CD56 ADC Products are also available for you.

Introduction of CD56

The glycoprotein CD56, also known as NCAM1, is a member of the neural cell adhesion molecule family that plays vital functional roles during development, nervous system differentiation, and immune surveillance. CD56 is primarily expressed on neuroendocrine, natural killer (NK) cells, and T cell lineages. Aberrant CD56 expression is also observed in a variety of malignancies such as multiple myeloma (MM), myelocytic and lymphocytic leukemia, small cell lung cancer (SCLC), and Merkel-cell carcinoma (MCC).

Fig.1 CD56 in the immune system. (Van Acker, 2017)

Anti-CD56 ADC in SCLC, Multiple Myeloma, Merkel-cell Carcinoma

The strong expression of CD56 in many cancers, along with its uniform distribution and cell membrane localization pattern, suggests that targeting CD56 may be a promising strategy for development of a therapeutic for SCLC, MM, and MCC. Conventional chemotherapy for those cancers is directed against all rapidly dividing cells, while targeted therapies focus on either the tumor cells or the peritumoral environment. As a novel therapy for cancer treatment, ADC shows great potential by target delivery of cytotoxin to cancer site. For example, lorvotuzumab mertansine (LM, IMGN901), was developed and tested for drug tumor-selective delivery. LM is an ADC comprising a humanized anti-CD56 monoclonal antibody covalently coupled, via disulfide linkage, to the cytotoxic maytansinoid DM1. LM binds with high affinity and specificity to CD56 on the surface of tumor cells-resulting in internalization of the ADC and subsequent intracellular release of DM1 due to cleavage of its disulfide bond with the linker. Phase 1 study investigated the safety, tolerability, pharmacokinetics, and preliminary activity of LM in patients with CD56-positive cancers and shows that LM has high-affinity, antigen-specific binding and robust antitumor activity in studied CD56-positive tumors.

Fig.2 Structure of lorvotuzumab mertansine. (Berdeja, 2014)

What Can We Do for You Concerning Anti-CD56 ADC?

As a well-recognized service provider in ADC preparation, Creative Biolabs guarantees that high specific anti-CD56 antibody can be genreated, and diverse Drug Module or Linker Module as well as various Drug-linker Complexes are also available for your. Through years of accumulation and exploration in the ADC industry, Creative Biolabs has established elaborate technology platforms to offer our clients one-stop ADC development services. If you are looking for a ADC developing partner, please don’t hesitate to contact us for more information.

Fig.3 Mechanism of action of ADC.

References

1. Van Acker, H. H.; et al. CD56 in the immune system: more than a marker for cytotoxicity? Frontiers in immunology. 2017, 8: 892.
2. Berdeja, J. G. Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma. Front Biosci (Landmark Ed). 2014, 19: 163-170.

For Research Use Only. NOT FOR CLINICAL USE.